AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02525757
Drug: MPDL3280A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation.
Trial: NCT02546986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
Trial: NCT03944434
Drug: Aromatase Inhibitors, non steroideal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
Trial: NCT03816696
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
Trial: NCT04421677
Drug: Phenylbutyrate Oral Tablet
RxNorm normalized name: phenylbutyrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
Trial: NCT04196231
Drug: Insulin/Dapaglifozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
Trial: NCT04196231
Drug: Insulin/Empaglifozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c \>7.5 after 12 weeks).
Trial: NCT01007383
Drug: LEO 27847
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First in man
Trial: NCT04196231
Drug: Basal Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose \< 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
Trial: NCT02183220
Drug: Acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183220
Drug: Metamizol placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183220
Drug: ASA placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04052516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral capsule
Trial: NCT03820804
Drug: Sapropterin
RxNorm normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
Trial: NCT04205812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
Trial: NCT02723539
Drug: MBN-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT01373021
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 2500mcg+NS50ml
Trial: NCT02723539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02027155
Drug: AR09 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moderate levels of sedation
Trial: NCT02027155
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Saline, USP
Trial: NCT02030808
Drug: Muscle Relaxants (MR) group
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
Trial: NCT02030808
Drug: Non- Muscle Relaxants (NMR) group
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cisatracurium® (Nimbex) will be administered
Trial: NCT03710772
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03710772
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03710772
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03406377
Drug: OPK-88003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPK-88003 subcutaneous injection
Trial: NCT03406377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection
Trial: NCT00852683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg twice a day
Trial: NCT01704079
Drug: CTAP101 30 μg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTAP101 30 μg capsule taken daily at bedtime
Trial: NCT03587116
Drug: Standard of Care FIX Replacement therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
Trial: NCT03587116
Drug: Standard of Care FVIII Replacement therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
Trial: NCT01703910
Drug: arm B chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00394095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo to Experimental arm
Trial: NCT02849418
Drug: GSK1358820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
Trial: NCT02849418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection contains sodium chloride (0.9 milligrams \[mg\]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
Trial: NCT01517399
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 200 mg oral tablet once alone and once again with tivantinib
Trial: NCT03380806
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard LHRH agonist for 3 years
Trial: NCT03995641
Drug: marcaine and kenalog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
Trial: NCT00144807
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00144807
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02662309
Drug: MPDL3280A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT01954992
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
Trial: NCT01523171
Drug: SAR302503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT03379168
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone is a standard of care injection to reduce joint inflammation.
Trial: NCT02040376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
Trial: NCT00992108
Drug: chemodenervation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: botulinum toxin
Trial: NCT04497012
Drug: 2mg/kg/day Iron Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
Trial: NCT04497012
Drug: 6 mg/kg/day Iron Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
Trial: NCT00607776
Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drops
Trial: NCT04106557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules to OV101 capsules.
Trial: NCT03175367
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC or IV administration
Trial: NCT03123692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days treatment with placebo
Trial: NCT01533207
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02561884
Drug: Olostar Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02561884
Drug: Co-administration of Olmetec and Crestor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03320707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
Trial: NCT03671681
Drug: Prophylactic
RxNorm normalized name: Caries prophylactic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
Trial: NCT03484702
Drug: JCAR017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01918527
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally on days 1-14: 2000 mg/m2/day q3w
Trial: NCT00331201
Drug: SAFEstart
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00381810
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01803438
Drug: Antiarrhythmic Drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
Trial: NCT04457297
Drug: trifluridine and tipiracil
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
Trial: NCT04457297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
Trial: NCT04445285
Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses
Trial: NCT03331315
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03331315
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00213044
Drug: Carraguard (PC-515)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02675465
Drug: ATB200
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02309346
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
Trial: NCT04418024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active control
Trial: NCT03169777
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03169777
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03169777
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT03279081
Drug: Cx601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cx601 eASCs intralesional injection.
Trial: NCT00611936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04160117
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
Trial: NCT01365923
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil effect site-TCI 2-4ng/ml
Trial: NCT01365923
Drug: dexmedetomidine with remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
Trial: NCT00274586
Drug: Aggrenox® modified release capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00274586
Drug: Aggrenox® modified release capsules matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00352768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01052493
Drug: PP 1420
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
Trial: NCT01052493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT02135250
Drug: Xinkeshu tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Xinkeshu tablets are given three times per day
Trial: NCT01521117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
Trial: NCT03923166
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 500mg tid
Trial: NCT01105429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0mg, once daily, 1 day
Trial: NCT01105429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, (TBD), once daily, 2 days
Trial: NCT00771758
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
Trial: NCT05056935
Drug: LB1148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
Trial: NCT05056935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Trial: NCT03931291
Drug: APR-246
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
Trial: NCT02005458
Drug: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02005458
Drug: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02005458
Drug: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03420963
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04707248
Drug: DS-6000a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
Trial: NCT04707248
Drug: DS-6000a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration at RDE on Day 1 of Cycle 1
Trial: NCT04747964
Drug: STSP-0601 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
Trial: NCT04747964
Drug: STSP-0601 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
Trial: NCT04747964
Drug: STSP-0601 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements
Trial: NCT04747964
Drug: STSP-0601 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
Trial: NCT04747964
Drug: STSP-0601 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
Trial: NCT04747964
Drug: STSP-0601 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
Trial: NCT03598842
Drug: Anti-parasitic medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
Trial: NCT03215069
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO daily
Trial: NCT00739648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same frequency as study drug using the same method of delivery
Trial: NCT02662374
Drug: .02% Chlorohexidine Gluconate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml of the drug in mouthwash form to be swished four times a day